Drugs / Gene-Transduced Autologous CD34+ Stem Cells
Gene-Transduced Autologous CD34+ Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00028236 | Dec 2001 → Jul 2011 | severe combined immunodeficiency | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gene-Transduced Autologous CD34+ Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00028236 ↗ |
| Modality | Cell therapy | “This is a Phase I/II clinical trial of ex vivo hematopoietic stem cell (HSC) gene therapy for X-linked severe combined immunodeficiency (XSCID).” NCT00028236 ↗ |